{
    "clinical_study": {
        "@rank": "21845", 
        "arm_group": {
            "arm_group_label": "Allogeneic Transplant and Immunotherapy", 
            "arm_group_type": "Experimental", 
            "description": "We intend to utilize reduced intensity conditioning and allogeneic stem cell transplant from HLA matched sibling or unrelated adult donor followed by post-AlloSCT Brentuximab Vedotin in patients with poor risk Hodgkin Lymphoma."
        }, 
        "brief_summary": {
            "textblock": "Patients with relapsed or refractory Hodgkin Lymphoma who are CD30+ will receive a standard\n      of care reduced intensity regimen and an allogeneic stem cell transplant (from another\n      person, related or unrelated). Following recovery, patients will receive a medication called\n      Brentuximab Vendotin which is targeted against CD30+ cells. The study hypothesis is that\n      this treatment will be safe and well tolerated in children and young adults."
        }, 
        "brief_title": "Immunotherapy Following Reduced Intensity Conditioning and Allogeneic Stem Cell Transplant for Poor Risk CD30+ Hodgkin Lymphoma Patients", 
        "completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Hodgkin Lymphoma", 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  45 years of age or less.\n\n          -  Patients with Hodgkin Lymphoma with either of the following:\n\n             \u2022 Primary induction failure (failure to achieve initial CR) and/or primary refractory\n             disease OR First, Second or Third relapse AND History of prior ablative auto HSCT or\n             ineligible for an ablative auto HSCT or \u226525% residual disease after at least two\n             reinduction chemotherapy cycles AND  HLA matched family donor (6/6 or 5/6) or matched\n             unrelated adult donor (MUD) (8/8) or matched umbilical cord blood unit (\u22655/6) with\n             prethaw cell dose of at least 3 x 107/kg TNC.\n\n          -  off other investigational therapy for one month prior to entry in this study.\n\n          -  adequate organ function\n\n        Exclusion Criteria:\n\n          -  Patients with HD with 4th or greater CR, PR, and/or SD are ineligible.\n\n          -  Patients with rapidly progressive disease (PD) unresponsive to reinduction chemo,\n             radio, or immunotherapy are ineligible.\n\n          -  Patients who don't have an eligible donor are ineligible.\n\n          -  Women who are pregnant are ineligible."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02098512", 
            "org_study_id": "NYMC 564"
        }, 
        "intervention": [
            {
                "arm_group_label": "Allogeneic Transplant and Immunotherapy", 
                "description": "Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:\n42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg  (max=180 mg) IV x 1\n63 (+/- 7 days)  Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1\n84 (+/- 7 days)  Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1\n105  (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1", 
                "intervention_name": "Brentuximab Vedotin", 
                "intervention_type": "Drug", 
                "other_name": "Adcetris"
            }, 
            {
                "arm_group_label": "Allogeneic Transplant and Immunotherapy", 
                "description": "Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.", 
                "intervention_name": "Allogeneic Stem Cell Transplantation", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": "Allogeneic Transplant and Immunotherapy", 
                "description": "Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide", 
                "intervention_name": "Reduced Intensity Conditioning", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Antibodies, Monoclonal"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Brentuximab Vedotin", 
            "Immunotherapy", 
            "Relapsed Hodgkin Lymphoma", 
            "Refractory Hodgkin Lymphoma", 
            "Reduced Intensity Conditioning", 
            "Allogeneic Stem Cell Transplantation"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "contact": {
                "email": "mitchell_cairo@nymc.edu", 
                "last_name": "Mitchell Cairo", 
                "phone": "914-594-2140"
            }, 
            "contact_backup": {
                "email": "jessica_hochberg@nymc.edu", 
                "last_name": "Jessica Hochberg, MD", 
                "phone": "914-594-2132"
            }, 
            "facility": {
                "address": {
                    "city": "Valhalla", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10595"
                }, 
                "name": "New York Medical College"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)", 
        "overall_contact": {
            "email": "mitchell_cairo@nymc.edu", 
            "last_name": "Mitchell Cairo, MD", 
            "phone": "914-594-2140"
        }, 
        "overall_contact_backup": {
            "email": "jessica_hochberg@nymc.edu", 
            "last_name": "Jessica Hochberg, MD", 
            "phone": "914-594-2132"
        }, 
        "overall_official": {
            "affiliation": "New York Medical College", 
            "last_name": "Mitchell Cairo, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Patients will be followed for one year for adverse events related to the administration of study drug.", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "1 year"
            }, 
            {
                "description": "patients will be assessed for one year to determine survival status", 
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02098512"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "A bank of from identified EBV positive donors will be established for potential use in current and future clinical trials in LMP-positive lymphomas. Annual review will occur to assess the feasibility of recruiting healthy donors to help build this cell line bank. If there are no cell lines developed within the first year, an alternative design may be considered.", 
            "measure": "To assess feasibility of developing a bank of LMP-specific CTLs from healthy donors", 
            "safety_issue": "No", 
            "time_frame": "3 years"
        }, 
        "source": "New York Medical College", 
        "sponsors": {
            "collaborator": {
                "agency": "St. Baldrick's Foundation", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "New York Medical College", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}